Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized placebo-controlled trial of rilzabrutinib in persistent or chronic immune thrombocytopenia
MOH_2021-02-18_009751Phase 3Recruiting
- Sponsor
- Principia Biopharma
- Start
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of rilzabrutinib in immune thrombocytopenia (ITP) (3 arms), sponsored by Principia Biopharma. Started Feb 2021; status: recruiting.
02
Drugs
rilzabrutinib
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on MOH_2021-02-18_009751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-02-18_009751.